Abstract
Overview
Introduction
Currently driven by the needs of the expanding respiratory market, the
inhalable drug delivery sector has also been invigorated by the promise of
growth through the systemic delivery of drugs via the lungs as the first
inhalable insulin nears the market. But whether the technology can deliver on
its promise has yet to be proven.
Scope
- Profiles of seven leading inhalable technology providers, benchmarking
their strategic outlook, financial position, technology platform and pipeline
- Evaluation of the growth potential of this sector of the drug delivery
market and the expected impact of systemic inhalable drugs reaching the market
- Analysis of the key issues affecting the inhalable drug delivery market
Report Highlights
Although currently driven by the respiratory market, demand for inhalable drug
delivery technology looks set to increase rapidly in the longer term if
systemic inhalable therapies can achieve their full potential
Generic drug manufacturers, such as Ivax, are increasingly developing or
acquiring the expertise to enhance generic pulmonary treatments by applying
proprietary technology. This represents a real threat to the current pulmonary
market value as the result would increase competition from cheaper branded
"super-generic" products
Inhalable devices provide a more patient-acceptable delivery for protein
therapeutics. However, the late stage inhalable insulin devices are bulky with
usability issues which may confuse and discourage the patient population and
act as a barrier to uptake. It is crucial that technological improvements are
made in order to ensure long term growth
Reasons to Purchase
- Understand the key drivers and resistors of growth within this area of
drug delivery
- Benchmark your position within the inhalable drug delivery market and
identify the optimum strategy for future growth
- Evaluate the comparative opportunities offered by the different
indications being targeted by inhalable therapies
View Cart
